Evidence map›Paper›PMID 32941540›Full record

ArticlePloS one2020

Survival of HIV-infected patients with high-grade non-Hodgkin's lymphomas: A retrospective study of experiences in Zimbabwe.

Maudy C P Manyau, Tinashe Mudzviti, Simbarashe Rusakaniko, Elson T Mberi, Charles C Maponga, Gene D Morse

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Maudy C P ManyauSchool of Pharmacy, College of Health Sciences, University of Zimbabwe, Mount Pleasant, Harare, Zimbabwe.ORCID 0000-0002-3772-1018
Tinashe MudzvitiSchool of Pharmacy, College of Health Sciences, University of Zimbabwe, Mount Pleasant, Harare, Zimbabwe.
Simbarashe RusakanikoDepartment of Community Medicine, College of Health Sciences, University of Zimbabwe, Avondale, Harare, Zimbabwe.
Elson T MberiDepartment of Hematology, College of Health Sciences, University of Zimbabwe, Avondale, Harare, Zimbabwe.
Charles C MapongaSchool of Pharmacy, College of Health Sciences, University of Zimbabwe, Mount Pleasant, Harare, Zimbabwe.
Gene D MorseCenter for Integrated Global Biomedical Sciences, University at Buffalo, Buffalo, New York, United States of America.
University of Zimbabwe · ZWUniversity at Buffalo, State University of New York · US

Funding

HIV Research Training ProgramD43TW010313 · FIC · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Charles Enos Chiedza Maponga, Gene D. Morse · 2016 to 2026
$3.2M
FIC NIH HHS D43 TW010313
6 · The paper itself

Abstract

backgroundRituximab in combination with chemotherapy is now widely accepted as standard of care for AIDS-related lymphomas (ARLs) of B-cell origin. However, the clinical impact of rituximab in resource limited settings remains unknown. Different settings and patient heterogeneity may affect the effect of any given treatment. The study objectives were to determine if rituximab use was associated with improved 18-month overall survival (OS) of patients with ARLs and to identify correlates of 18-month OS.

methodsA retrospective review of medical records of adult HIV infected patients treated for high-grade large cell non-Hodgkin's lymphoma with chemotherapy +/- rituximab between 2015-2017 was conducted. Vital status and disease progression/relapse at 18 months were determined. Survival functions were estimated using Kaplan-Meier methodology. Equality of survival functions were assessed using Log-rank tests and Cox regression analysis to identify risk factors for mortality.

resultsOne hundred and twenty-four eligible medical records were identified. This was a cohort of black Africans with a median age of 42 (IQR: 33-47) and a 57% male gender distribution. Overall survival at 6, 12 and 18 months for the population was 75.9%, 44.0% and 30.6% respectively. Over the study period, 72.6% of patients were diagnosed with disease progression/ relapse. There was a higher rate of rituximab use in patients who were treated at a private institution and those with medical insurance. Rituximab use was not associated with a reduction in 18-month mortality [adjusted hazard ratio (aHR)1.28, (95% CI 0.63-2.60)]. Risk factors for 18-month mortality were male gender [aHR 1.89, (95% CI 1.04-3.43)], age 40+ years [aHR 2.49, (1.33-4.67)], receipt of <3 chemotherapy cycles [aHR 2.48, (95% CI 1.33-4.60)] and low socioeconomic status [aHR 2.44, (95% CI 1.28-4.67)].

conclusionsPredictors of mortality were male gender, older age, low socioeconomic status and receipt of a less than half of the recommended number of chemotherapy cycles. Rituximab use was not associated with an improvement in 18-month OS in Zimbabwean patients with ARLs.

Indexed as

AdultAgedFemaleHumansLymphoma, AIDS-RelatedLymphoma, Non-HodgkinMaleMiddle AgedRetrospective StudiesRituximabSurvival AnalysisZimbabweRituximab

Identifiers

PMID32941540
PMCPMC7498086
OpenAlexW3087175747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.